Bain Capital Life Sciences Leads $107M Series C Financing of Jnana Therapeutics

Choate represented Bain Capital Life Sciences in the $107M Series C Financing of Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets. The financing was led by Bain Capital Life Sciences with participation from existing investors including RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, and Pfizer Ventures. The proceeds from the funding will be used to progress Jnana’s lead program in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and to advance additional wholly owned, potential first-in-class medicines in immune-mediated diseases and cancer.